0
0
Roche Reports Positive Phase-1 Results for CT-388 Weight Loss Drug
Roche, a leading Swiss pharmaceutical company, recently announced favorable outcomes from its phase-1 clinical trial of CT-388, an experimental weight loss medication. This significant development adds to the ongoing competition within the anti-obesity drug market, challenging the current duopoly maintained by Novo Nordisk with Ozempic and Eli Lilly with Zepbound and Mounjaro.
The Breakthrough: CT-388
CT-388 is a weekly injectable drug that falls under the same category of medication as Ozempic, designed to mimic gut hormones that regulate blood sugar levels and reduce the user’s appetite. This innovative approach has shown promising results in inducing weight loss among patients participating in the trial.
Morgan Stanley analysts predict that the global market for such medications could potentially reach a staggering $105 billion by 2030, reflecting the growing demand for effective weight management solutions.
Encouraging Results
According to Roche’s announcement, patients treated with CT-388 achieved remarkable weight loss outcomes. On average, participants experienced an 18.8% reduction in body weight after 24 weeks of consistent drug administration. Comparatively, a separate study on Novo Nordisk’s Wegovy indicated a 15% weight loss over a period of 68 weeks.
Furthermore, Roche disclosed that all individuals subjected to CT-388 treatment witnessed a minimum weight loss of 5%, with a notable 85% achieving a 10% or higher reduction, while 45% surpassed the 20% milestone. Such compelling statistics underscore the drug’s potential to revolutionize the obesity and type 2 diabetes treatment landscape.
Optimistic Outlook
Ruben Jones, Roche’s Chief Medical Officer, expressed enthusiasm over the trial results, emphasizing the significant and clinically meaningful impact of CT-388 on weight loss. Dr. Jones stated, “The results are highly encouraging for further development of CT-388 for both obesity and type 2 diabetes, highlighting its potential to emerge as a pioneering therapy with sustained weight loss benefits and enhanced glucose control.”
Moreover, the medication demonstrated favorable tolerability profiles, with mild to moderate gastrointestinal-related adverse events reported as the most prevalent side effects. Roche is currently exploring additional applications of CT-388 in the treatment of type-2 diabetes, emphasizing its versatility and potential to address multiple health concerns.
Overall, Roche’s successful phase-1 trial outcomes for CT-388 mark a significant milestone in the pursuit of effective weight loss solutions, signaling a new era of innovation and advancement in pharmaceutical research and development.
Image/Photo credit: source url
